tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PBIGF Stock Latest News

Paradigm Biopharmaceuticals Expands ASX Quotation with New Securities
Company AnnouncementsParadigm Biopharmaceuticals Expands ASX Quotation with New Securities
20h ago
Paradigm Biopharmaceuticals Secures US$27 Million in Convertible Notes Agreement
PremiumCompany Announcements
Paradigm Biopharmaceuticals Secures US$27 Million in Convertible Notes Agreement
16d ago
Paradigm Biopharmaceuticals Issues 7 Million Convertible Notes
PremiumCompany Announcements
Paradigm Biopharmaceuticals Issues 7 Million Convertible Notes
16d ago
Paradigm Biopharmaceuticals Completes Share Issuance Under Convertible Securities Agreement
PremiumCompany Announcements
Paradigm Biopharmaceuticals Completes Share Issuance Under Convertible Securities Agreement
21d ago
Paradigm Biopharmaceuticals Announces Quotation of New Securities
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Quotation of New Securities
21d ago
Paradigm Biopharmaceuticals Announces Convertible Notes Issue
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Announces Convertible Notes Issue
22d ago
Paradigm Biopharmaceuticals Announces Proposed Securities Issue
Premium
Company Announcements
Paradigm Biopharmaceuticals Announces Proposed Securities Issue
22d ago
Paradigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Study in the US
Premium
Company Announcements
Paradigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Study in the US
23d ago
Paradigm Biopharmaceuticals Expands Osteoarthritis Portfolio with New Acquisition
PremiumCompany Announcements
Paradigm Biopharmaceuticals Expands Osteoarthritis Portfolio with New Acquisition
27d ago
Paradigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Trial
PremiumCompany Announcements
Paradigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Trial
2M ago
Paradigm Biopharmaceuticals’ General Meeting Results and Future Meeting Plans
PremiumCompany Announcements
Paradigm Biopharmaceuticals’ General Meeting Results and Future Meeting Plans
2M ago
Paradigm Biopharmaceuticals Secures US Ethics Approval for Phase 3 Osteoarthritis Trial
PremiumCompany Announcements
Paradigm Biopharmaceuticals Secures US Ethics Approval for Phase 3 Osteoarthritis Trial
2M ago
Paradigm Biopharmaceuticals Seeks Shareholder Approval for Strategic Resolutions
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Seeks Shareholder Approval for Strategic Resolutions
3M ago
Paradigm Biopharmaceuticals Advances Phase 3 Trial for Osteoarthritis Treatment
Premium
Company Announcements
Paradigm Biopharmaceuticals Advances Phase 3 Trial for Osteoarthritis Treatment
3M ago
Paradigm Biopharmaceuticals to Present at NWR Virtual Healthcare Conference
Premium
Company Announcements
Paradigm Biopharmaceuticals to Present at NWR Virtual Healthcare Conference
4M ago
Paradigm Biopharmaceuticals Reports Reduced Losses Amid Ongoing Osteoarthritis Treatment Development
PremiumCompany Announcements
Paradigm Biopharmaceuticals Reports Reduced Losses Amid Ongoing Osteoarthritis Treatment Development
5M ago
Paradigm Biopharmaceuticals Secures Ethics Approval for Phase 3 Osteoarthritis Trial
PremiumCompany Announcements
Paradigm Biopharmaceuticals Secures Ethics Approval for Phase 3 Osteoarthritis Trial
5M ago
Paradigm Biopharmaceuticals Director Acquires New Options
PremiumCompany Announcements
Paradigm Biopharmaceuticals Director Acquires New Options
5M ago
Paradigm Biopharmaceuticals Announces Director’s Securities Interest Update
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Director’s Securities Interest Update
5M ago
Paradigm Biopharmaceuticals Issues New Securities to Bolster Strategic Initiatives
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Issues New Securities to Bolster Strategic Initiatives
5M ago
Paradigm Biopharmaceuticals Amends Bonus Issue Announcement
Premium
Company Announcements
Paradigm Biopharmaceuticals Amends Bonus Issue Announcement
6M ago
Paradigm Biopharmaceuticals Announces Strategic Bonus Issue of Securities
Premium
Company Announcements
Paradigm Biopharmaceuticals Announces Strategic Bonus Issue of Securities
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >